摘要
目的:观察咳喘宁对支气管哮喘大鼠肺组织干扰素γ(IFN-γ)、白介素4(IL-4)含量的影响。方法:以卵蛋白致敏并吸入激发法制备大鼠支气管哮喘模型,各治疗组均从第1次哮喘激发开始(造模第3周)至处死前每天灌胃给药,激发并给药4周后处死大鼠,观察各组大鼠肺组织IFN-γ和IL-4含量和病理组织学变化。结果:与正常组比较,模型组大鼠支气管管壁和平滑肌厚度、嗜酸性粒细胞、淋巴细胞数以及肺组织IL-4含量明显增加,IFN-γ和IL-4比值明显降低,IFN-γ含量有所升高,但无显著性差异;与模型组比较,各治疗组均可显著降低支气管管壁和平滑肌厚度、嗜酸性粒细胞、淋巴细胞数以及肺组织IL-4含量,升高IFN-γ含量以及IFN-γ和IL-4比值;且咳喘宁高剂量组优于桂龙咳喘宁组。结论:咳喘宁可通过调节Th1/Th2细胞因子之间的平衡,抑制气道炎症。
Objective: To observe effect of Kechuanning on the contents of interferon-γ(IFN-γ) and interleukin 4 (IL-4) in lung tissue of bronchial asthmatic rats. Methods: 40 rats were randomly divided into 5 groups: the normal group, the model group, Kechuanning high-dose group (27g/kg), Kechuanning low-dose group(13.5g/kg) , Guilongkechuanning control group(0.45g/kg) ,8 rats each group. The bronchial asthmatic model was established by egg protein sensibilization and long-term inhalation provocation. The rats of each treatment groups were lavage administration each day from the first time of provocation to execution. After 4 weeks of treatment, the rats were killed and lung tissue were taken to dyeing of HE to be observed. The contents of IFN-γ,and IL-4 in lung tissue were determined. Result: Compared with the normal group, the thickness of bronchus wall and bronchus smooth muscle, the numbers of eosinophile granulocyte and leukomonocyte, and the content of IL-4 in lung tissue were increased and the ratio of IFN-γ / IL-4 were decreased in the model group( P 〈0.01 ) , the content of IFN- γ,were increased, but not remarketable different( P 〉 0.01 ) ; Compared with the model group, the thickness of bronchus wall and bronchus smooth muscle, the numbers of eosinophile granulocyte and leukomonocyte, the content of IL-4 in lung tissue were decreased and the content of IFN-γand the ratio of IFN-γ / IL-4 were increased in each treatment group ( P 〈 0.05 or P 〈 0.01 ), furthermore, the effect of high-dose Kechuanning group were super to that of Guilongekechuanning group ( P 〈 0.05). Conclusion: The Kechuanning could regulate the banlance of cytokines Thl and Th2 to restrain air passage inflammation.
出处
《中药药理与临床》
CAS
CSCD
北大核心
2008年第2期93-94,共2页
Pharmacology and Clinics of Chinese Materia Medica
基金
河北省科技攻关计划项目(06276102D-37)